Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
2 hedge funds and large institutions have $226K invested in Global X China Biotech Innovation ETF in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.
16% more capital invested
Capital invested by funds: $194K → $226K (+$32K)
33% less funds holding
Funds holding: 3 → 2 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$251K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$180K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$14.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $225K | +$251K | +24,943 | New |
|
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$1K | +100 | New |
|
|
3
Jane Street
New York
| – | -$180K | -19,093 | Closed |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$14.5K | -1,538 | Closed |
|
CHB Hedge Fund Activity: Q1 2023 in Review
2 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q1 2023, worth a combined $226K — up 16% from $194K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CHB and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $251K. The largest seller was Jane Street, exiting entirely with an estimated $180K sold.
- 2 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q1 2023, down from 3 in Q4 2022.
- Funds reported $226K of Global X China Biotech Innovation ETF stock for Q1 2023, up 16% quarter-over-quarter.
- 2 funds opened new Global X China Biotech Innovation ETF positions in Q1 2023 and 3 closed out, a net change of -1 holder.
- The largest Global X China Biotech Innovation ETF buyer in Q1 2023 was Citadel Advisors, an estimated $251K added.
- The largest Global X China Biotech Innovation ETF seller in Q1 2023 was Jane Street, an estimated $180K sold.
Based on aggregated 13F filings for Q1 2023.